No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 3.1x · 10Y median 13.8x · 1st percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 27
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:01:39.625Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T14:01:39.625Z. Latest historical point 2023-05-08. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T14:01:39.625Z. Latest historical point 2023-05-08. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T14:01:39.625Z. Latest historical point 2023-05-08. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T14:01:39.625Z. Latest historical point 2023-05-08. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Foghorn Therapeutics Inc. (FHTX) stock was $1.95 as of Oct 6, 2026, 9:59 AM EDT, down 2.54% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -56.7% · 3-year avg -22.2%/yr · 5-year avg -31.9%/yr
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines.
Biotechnology · Watertown, MA
Next Earnings Date
Nov 4, 2026
29 days away
EPS Estimate
-0.23
Revenue Est.
$6.39M
Last Quarter Results
EPS
$-0.10
vs Estimate
$-0.23
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1FHTX | $114.45M | $1.95 | -2.54% | -56.72% | -31.87% | N/A | N/A |
| 2COYA | $114.94M | $4.90 | +1.03% | -20.40% | N/A | N/A | vs FHTX |
| 3LUCD | $113.78M | $0.60 | +0.52% | -42.80% | N/A | N/A | vs FHTX |
| 4LENZ | $116.25M | $3.71 | +3.28% | -92.54% | -35.49% | N/A | vs FHTX |
| 5GNLX | $116.36M | $2.60 | -0.19% | -41.42% | N/A | N/A | vs FHTX |
| 6AARD | $111.33M | $5.09 | -2.54% | -67.36% | N/A | N/A | vs FHTX |
forward FY estimate
N/A
$16.10M
vs Estimate
$6.81M
Consensus Rating
Based on 6 analysts
Average Price Target
$6.00
+207.8% upside
Low
$2.00
Current
$1.95
High
$14.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.31 | $-0.25 | $-0.18 | 6 |
| Quarter ending Dec 2026 | $-0.31 | $-0.25 | $-0.19 | 6 |
| Quarter ending Mar 2027 | $-0.53 | $-0.23 | $-0.03 | 2 |
| Quarter ending Jun 2027 | $-0.52 | $-0.23 | $-0.03 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.97 | $-0.91 | $-0.78 | 7 |
| FY 2027 | $-1.27 | $-0.93 | $-0.66 | 7 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $2.79M | $6.39M | $10.26M | 6 |
| Quarter ending Dec 2026 | $958363.00 | $3.00M | $5.99M | 6 |
| Quarter ending Mar 2027 | $770866.00 | $2.42M | $4.82M | 3 |
| Quarter ending Jun 2027 | $770866.00 | $2.42M | $4.82M | 3 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $22.63M | $28.72M | $38.12M | 8 |
| FY 2027 | $2.98M | $10.79M | $18.60M | 7 |
